HealthQuest Capital leads financing to support Aliya commercial expansion, clinical evidence generation, pipeline advancement, and development of next-generation pulsed electric field ablation platforms
REDWOOD CITY, Calif., Nov. 16, 2026 /PRNewswire/ — Galvanize Therapeutics®, a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease, today announced the closing of an oversubscribed $130 million Series D financing.
The round was led by HealthQuest Capital, a growth equity firm focused on commercial-stage healthcare companies. Olympus Innovation Ventures and Braidwell LP also joined the round as new investors.
Existing investors Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company, and T. Rowe Price Associates, Inc. also participated in the round.
Over the past year, Galvanize has built significant commercial, clinical, and technological momentum. Key milestones include FDA clearance and commercial launch of the next-generation Aliya EX Generator, expanding physician adoption of Aliya® PEF technology, and surpassing 4,000 procedures performed. The company has also strengthened its clinical evidence program, enrolling more than 300 patients in its PROPEL registry and contributing to a growing body of scientific literature that includes over 40 peer-reviewed publications exploring PEF mechanisms of action, clinical outcomes, and potential applications across oncology and chronic disease.
“This financing marks an important inflection point for Galvanize,” said Doug Godshall, Chairman and Chief Executive Officer of Galvanize Therapeutics. “We’ve built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution, and an expanding body of clinical evidence. This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease. We’re grateful for the continued confidence of our investors as we enter this next phase of growth.”
Proceeds from the financing will support continued commercial expansion of Aliya, investment in clinical evidence generation, advancement of RheOx® therapy for chronic bronchitis, and development of next-generation PEF products and platforms.
“We have followed Galvanize’s progress closely over the years and are thrilled to back the company as it enters its next phase of growth,” said Garheng Kong, MD, PhD, Founder and Managing Partner of HealthQuest Capital. “Galvanize has built a differentiated PEF platform with the potential to meaningfully advance care in interventional oncology and pulmonology. We are excited to partner with the exceptional team as they expand the reach and impact of their innovative technology.”
In connection with the financing, Garheng Kong will join the Galvanize Board of Directors.
About Aliya PEF Ablation
Aliya EX is the next-generation generator for the Aliya PEF System, delivering high-voltage, short-duration electrical energy to induce non-thermal regulated cell death during the surgical ablation of soft tissue. Preclinical and early clinical data suggest Aliya PEF may promote antigen release that could activate the immune system; the effectiveness of the Aliya System for the induction of an immune response resulting in patient benefit has not been established.
About Galvanize Therapeutics
Galvanize Therapeutics is pioneering pulsed electric field technologies designed to harness biological processes for applications in oncology and chronic lung disease. Headquartered in Redwood City, California, the company is commercializing its Aliya PEF platform in the United States while advancing a pipeline of innovative technologies and applications across oncology and chronic disease. For more information, please visit www.galvanizetx.com.
About HealthQuest Capital
HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately $2 billion in committed capital, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry. For more information, visit www.healthquestcapital.com.
Regulatory Statement
The Aliya PEF System is 510(k) cleared in the United States for the surgical ablation of soft tissue. The Aliya PEF System is not currently commercially available in any other geography. Galvanize Therapeutics does not promote the off-label use of its products. The Aliya PEF System is a tool for the surgical ablation of soft tissues and is not intended to treat, cure, prevent, or mitigate any specific disease or condition.
RheOx is an investigational device in the United States and is limited by Federal law to investigational use.
SOURCE Galvanize Therapeutics, Inc.



